Q-omics provides the consensus-scored CITED2 profile across patient tissues and cancer cell-line models. CITED2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, CITED2 is differentially expressed in 16, with the highest sampling consensus in COAD. Additionally, CITED2 RNA expression shows 18,526 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight OV, COAD, and KIRP as cancer lineages where CITED2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CITED2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CITED2 survival associations across molecular data types. CITED2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CITED2 RNA expression–survival associations across cancer types. High CITED2 expression shows unfavorable associations in OV, STAD, CESC and LGG, but favorable associations in KIRC and UCS. The OV Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify OV as the clearest survival context for CITED2 RNA expression.
This table summarizes CITED2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 4. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CITED2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CITED2 shows lower tumor expression in COAD, THCA, LUAD, HNSC, KICH and BLCA. The COAD box plot shows higher CITED2 RNA expression in normal versus tumor tissue (log2 FC = −1.775, t-test p < 0.001).
This table shows molecular features associated with CITED2 in patient tissues and cancer cell lines. In patient samples, CITED2 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, CITED2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
